



November 9, 2017

Terumo Revises Upward Interim Dividends and Year-End Dividends Forecast for the Fiscal Year Ending March 31, 2018

TOKYO, JAPAN – November 9, 2017 – Terumo Corporation (TSE: 4543) resolved, at its Board of Directors meeting held on November 9, 2017, the interim dividends and year-end dividends forecast for the fiscal year ending March 31, 2018 as follows.

1. Details of Interim Dividends

| | Decided dividends | Latest dividends forecast (as of May 10, 2017) | FY 2017 Interim dividends (Actual) |
|---------------------------------|--------------------|---|--|
| Record date | September 30, 2017 | September 30, 2017 | September 30, 2016 |
| Dividends per share | ¥23.00 | ¥22.00 | ¥20.00 |
| Total amount of dividends | ¥8,095 million | - | ¥7,259 million |
| Dividends payment starting date | December 5, 2017 | - | December 7, 2016 |
| Source of dividends | Retained earnings | - | Retained earnings |

2. Details of Dividends Forecast Modifications

| Record date | Dividends per share | | |
|---|--------------------------------|----------|--------|
| | End of 2 nd quarter | Year-end | Annual |
| Prior forecast | ¥22.00 | ¥22.00 | ¥44.00 |
| Revised forecast | | ¥23.00 | ¥46.00 |
| FY 2017 actual (ending March 31, 2018) | ¥23.00 | | |
| FY 2016 actual (ended March 31, 2017) | ¥20.00 | ¥22.00 | ¥42.00 |

3. Reasons for Modifications

Terumo considers the distribution of an appropriate amount of profit to shareholders to be one of the principal responsibilities of management and pays dividends in accordance with a policy of stably and steadily increasing dividends with a target payout ratio of 30% over the medium to long-term. Based on the policy and financial results, Terumo decided the interim dividends of ¥23 per share and the year-end dividends forecast of ¥23 per share respectively.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

###